EMEA-001748-PIP03-19

Key facts

Active substance
arimoclomol citrate
Therapeutic area
Neurology
Decision number
P/0012/2021
PIP number
EMEA-001748-PIP03-19
Pharmaceutical form(s)
Capsule, hard
Condition(s) / indication(s)
Treatment of amyotrophic lateral sclerosis
Route(s) of administration
Oral use
Contact for public enquiries
Orphazyme A/S

Email: contact@orphazyme.com
Tel. +45 39178272

Decision type
P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)

Decision

How useful was this page?

Add your rating